First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Recent developments in clinical trials and potential partnerships have shifted investor sentiment positively, suggesting a possible turnaround in revenue generation.
★ Analysts see FY2026 revenue reaching $62M — +46.1% growth in a single year.
Why Revenue Could Explode
1Coherus is in discussions with a major pharmaceutical company for a potential partnership to co-develop a new oncology biosimilar, which could significantly enhance its market presence.
2Recent data from clinical trials shows a 30% improvement in efficacy for a new biosimilar candidate, which could lead to expedited FDA approval.
3Market analysis indicates a 25% increase in demand for oncology biosimilars over the next two years, positioning Coherus favorably if it can capture market share.
4A competitor's recent product recall could provide Coherus with an opportunity to gain market share in the oncology biosimilar space.
5Growth in the oncology biosimilars market
6Increased focus on cost-effective cancer treatments
"Management stated, 'We are optimistic about our pipeline and the potential partnerships that could enhance our market position.'"
Moat: Coherus has a moderate moat due to its established product and regulatory approvals, but faces increasing competition.
growth - Investors looking for potential upside from biosimilar market growth and FDA approvals.
Higher interest rates could increase the cost of capital for Coherus, impacting its ability to finance R&D and operational expenses…
Watch on earnings: Sales growth of Udenyca, Market share in oncology biosimilars, Operating cash flow.
One Sentence Summary:
The bull case is simple: analysts see revenue climbing from $62M to $88M as coherus is in discussions with a major pharmaceutical company for a potential partnership to co-develop a new oncology.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.